Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
Late diagnosis of breast cancer significantly impacts survival — and men are generally diagnosed with breast cancer at more advanced stages.
Phase 3 clinical trial of paclitaxel and atezolizumab shows no significant survival benefit, but questions remain over FDA decision to issue safety alert.
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
A new approach combining inducible gene therapy and an anti–PD-1 shows promise in hard-to-treat brain tumors.
The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.
